DEA schedule
Is Reyvow a controlled substance?
Reyvow contains lasmiditan. Federal schedule from the FDA NDC directory, checked against the DEA controlled substances list.
Source: FDA NDC Directory file dated 2026-10-22. Publisher page
Yes. Reyvow (lasmiditan) is a Schedule V controlled substance under the federal Controlled Substances Act. Matching DEA list entry: Lasmiditan (Schedule V).
Run it in Rivvi
Which 2027 plans near you dropped or restricted Reyvow?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Schedule check
| Source | What it lists |
|---|---|
| FDA NDC directory | 2 prescription listings from 1 labelers, all Schedule V |
| DEA controlled substances list | Lasmiditan [2,4,6-trifluoro-N-(6-(1-methylpiperidine-4- carbonyl)pyridine-2-yl-benzamide]: Schedule V |
DEA list entry
| Substance | DEA code | Schedule | Narcotic | Other names | Match |
|---|---|---|---|---|---|
| Lasmiditan [2,4,6-trifluoro-N-(6-(1-methylpiperidine-4- carbonyl)pyridine-2-yl-benzamide] | 2790 | V | No | Reyvow | Listed by name |
Reyvow NDC listings
Questions
Is Reyvow a controlled substance?
Yes. Reyvow (lasmiditan) is a Schedule V controlled substance under the federal Controlled Substances Act. Matching DEA list entry: Lasmiditan (Schedule V).
Is Reyvow a narcotic?
No. The DEA list does not mark lasmiditan as a narcotic (NARC = N) and places it in Schedule V.
What schedule is Reyvow?
Reyvow is Schedule V in the FDA NDC directory, which matches the DEA controlled substances list.
Does this page cover state schedules?
No. This page reports the federal schedule only. Some states schedule drugs on their own; check your state board of pharmacy.